Skip to main content

Table 4 Management of adverse reactions

From: Adverse infusion reactions to rituximab in systemic lupus erythematosus: a retrospective analysis

Management No. % of total reactions Retreated?
Able to resume/complete infusion 8 28.6% Y - 1 (2 further cycles with reaction)
Had to cease infusion 7 25.0% Y - 1 (2 further cycles)
Hospital Admission > 24 h 3 10.7% Y - 1 (1 further cycle) reaction)
Delayed reaction 5 17.9% Y - 1 (1 further cycle)
Unclassifieda 4 14.3% N
Death 1 3.6% n/a
  1. aDue to lack of clinical data